Download Documentation Expanded Approval & Q3 2017 Results Webcast Presentation
Download Documentation Q2 2017 Earnings Conference Call Presentation
Download Documentation Q1 2017 Earnings Conference Call Presentation

Corporate Profile

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with renal disease and their healthcare providers. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine. Patients have been and continue to be at the center of our nearly 20-year corporate history.

Keryx established its corporate headquarters in Boston to support the U.S. launch of its first medicine. Joining Boston’s pioneering biotech community has given us the opportunity to bring together a seasoned talent pool of innovative minds and resources that will allow us to continue toward our goal of building a leading renal company. We are a rapidly growing company, with approximately 200 employees across Boston and our field teams.

Stock Quote

KERX (Common)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.18 (3.80%)
Data as of 12/11/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Report

View the 2016 Annual Report on Form 10K  - PDF View the 2016 Annual Report on Form 10K

Recent News

11/08/17Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in November 2017Printer Friendly Version
11/07/17U.S. FDA Approves Auryxia® (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on DialysisPrinter Friendly Version
11/07/17Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results   Printer Friendly Version
11/06/17Keryx Biopharmaceuticals Moves Third Quarter 2017 Financial Results Call to Tuesday, November 7, 2017 at 8:00 a.m. ETPrinter Friendly Version

Upcoming Events

There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.